9,12,20-Trioxo-8,19-bis(phenylmethoxy)-2,8,13,19-tetraazatricosanedioic Acid 1-(1,1-Dimethylethyl) Ester is an intermediate in synthesizing Deferoxamine-d7 TFA Salt (D228982), a labelled Deferoxamine Mesylate (D228980), which is an iron chelating agent used in therapy for patients with sickle cell diseases and iron overload. Studies suggest that it can exert potential antioxidant neuroprotective effects in stroke patients.